Quantification of co-trimoxazole in serum and plasma using MS/MS

Jacob A Dijkstra, Noor Si Alsaad, Kai van Hateren, Ben Greijdanus, Daan J Touw, Jan-Willem C Alffenaar

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Co-trimoxazole is frequently used in the prophylaxis and treatment of Pneumocystis carinii pneumonia. High plasma concentrations of sulfamethoxazole or trimethoprim are correlated with toxicity. There is, however, a large variation in PK observed which can lead to underexposure or toxicity.

RESULTS: We developed a novel LC-MS/MS method to analyze the components of co-trimoxazole, trimethoprim and sulfamethoxazole and its metabolite sulfamethoxazole-N-acetyl. This new method is expeditious due to its limited sample preprocessing and a relatively short run-time of only 3 min.

CONCLUSION: This new method met the US FDA requirements on linearity, selectivity, precision, accuracy, matrix effects, recovery and stability and is suitable for routine analysis and future prospective studies.

Original languageEnglish
Pages (from-to)2741-9
Number of pages9
JournalBioanalysis
Volume7
Issue number21
DOIs
Publication statusPublished - Nov 2015

Cite this

Dijkstra, J. A., Alsaad, N. S., Hateren, K. V., Greijdanus, B., Touw, D. J., & Alffenaar, J-W. C. (2015). Quantification of co-trimoxazole in serum and plasma using MS/MS. Bioanalysis, 7(21), 2741-9. https://doi.org/10.4155/bio.15.188